US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Tourmaline Bio, Inc. - Common Stock (NQ:TRML)

47.98 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tourmaline Bio, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
News headline image
Trip.com Posts Weak Earnings, Joins Vipshop, Viking Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
What's going on in today's pre-market session ↗
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Present at Upcoming Investor Conferences
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Present at Upcoming Investor Conferences
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024 ↗
TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
From Tourmaline Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >